regardless of promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. The insurers are typically creating limitations to access, like steep expense restrictions and a